Terms: = Germ cell tumor AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12
1937 results:
1. Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies.
Huai JX; Wang F; Zhang WH; Lou Y; Wang GX; Huang LJ; Sun J; Zhou XQ
Front Endocrinol (Lausanne); 2024; 15():1484815. PubMed ID: 39439561
[TBL] [Abstract] [Full Text] [Related]
2. Sporadic and Familial Medullary Thyroid Carcinoma: A retrospective Single Center Study on Presentation and Outcome.
Prinzi A; Vella V; Bosco A; Mirone A; Russo M; Piticchio T; Di Benedetto G; Bartoloni G; Frasca F; Malandrino P
Endocr Res; 2024; 49(4):179-185. PubMed ID: 39419111
[TBL] [Abstract] [Full Text] [Related]
3. Molecular genetics, therapeutics and ret inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Zhang Y; Zheng WH; Zhou SH; Gu JL; Yu Q; Zhu YZ; Yan YJ; Zhu Z; Shang JB
Cell Commun Signal; 2024 Sep; 22(1):460. PubMed ID: 39342195
[TBL] [Abstract] [Full Text] [Related]
4. Thyroid Malignancy and Cutaneous Lichen Amyloidosis: Key Points Amid
Stanescu LS; Ghemigian A; Ciobica ML; Nistor C; Ciuche A; Radu AM; Sandru F; Carsote M
Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337252
[TBL] [Abstract] [Full Text] [Related]
5. PRAP study-partial versus radical adrenalectomy in hereditary pheochromocytomas.
Xu K; Langenhuijsen JF; Viëtor CL; Feelders RA; van Ginhoven TM; Elhassan YS; Bioletto F; Parasiliti-Caprino M; Zandee WT; Kruijff S; Backman S; Åkerström T; Pamporaki C; Bechmann N; Lussey-Lepoutre C; Canu L; Steenaard RV; Driessens N; Velema M; Dreijerink KMA; Engelsman AF; Timmers HJLM; de Laat JM
Eur J Endocrinol; 2024 Aug; 191(3):345-353. PubMed ID: 39171965
[TBL] [Abstract] [Full Text] [Related]
6. Clues for Early Diagnosis of men2b Syndrome Before Medullary Thyroid Carcinoma.
Taylor-Miller T; Tucker K; Sugo E; Anazodo A; Mowat D
Pediatrics; 2024 Sep; 154(3):. PubMed ID: 39148481
[TBL] [Abstract] [Full Text] [Related]
7. Fluctuating obliterative bronchiolitis in ret-mutant medullary thyroid cancer patient treated with selpercatinib.
Gambale C; Prete A; Romei C; Celi A; Elisei R; Matrone A
Eur Thyroid J; 2024 Oct; 13(5):. PubMed ID: 39136571
[TBL] [Abstract] [Full Text] [Related]
8. High success rate of first proficiency testing for ret fusions and ret mutations in lung and thyroid cancer samples by various methods.
Siebolts U; Pappesch R; Bauer M; Dietmaier W; Ernst M; Haak A; Hartmann N; Ilm K; Kalbourtzis S; Krause T; Kazdal D; Schorle H; Utpatel K; Merkelbach-Bruse S
Virchows Arch; 2024 Sep; 485(3):519-526. PubMed ID: 39120655
[TBL] [Abstract] [Full Text] [Related]
9. Durability of Response With Selpercatinib in Patients With
Wirth LJ; Brose MS; Subbiah V; Worden F; Solomon B; Robinson B; Hadoux J; Tomasini P; Weiler D; Deschler-Baier B; Tan DSW; Maeda P; Lin Y; Singh R; Bayt T; Drilon A; Cassier PA
J Clin Oncol; 2024 Sep; 42(27):3187-3195. PubMed ID: 39094065
[No Abstract] [Full Text] [Related]
10. Pheochromocytoma/paraganglioma type 5 syndrome as a cause of secondary hypertension in a Colombian patient: case report.
Morales J; Arturo D; Folleco M
Biomedica; 2024 May; 44(Sp. 1):18-26. PubMed ID: 39079135
[TBL] [Abstract] [Full Text] [Related]
11. germline Mutations and Phenotypic Associations in Korean Patients With Pheochromocytoma and Paraganglioma: A Multicenter Study and Literature Review.
Jo KH; Lee J; Yoo J; Kim HS; Kim ES; Han JH; Jang YS; Yun JS; Son JW; Yoo SJ; Lee SH; Lim DJ; Kwon HS; Lee S; Moon S; Kim M
Ann Lab Med; 2024 Nov; 44(6):591-597. PubMed ID: 39069753
[TBL] [Abstract] [Full Text] [Related]
12. Multiple Endocrine Neoplasia Type 1, Type 2A, and Type 2B.
Greenberg LA
Prim Care; 2024 Sep; 51(3):483-494. PubMed ID: 39067973
[TBL] [Abstract] [Full Text] [Related]
13. Biomarker identification of medullary thyroid carcinoma from gene expression profiles considering without-treatment and with-treatment studies-A bioinformatics approach.
Loganathan T; George Priya Doss C
Adv Protein Chem Struct Biol; 2024; 142():367-396. PubMed ID: 39059991
[TBL] [Abstract] [Full Text] [Related]
14. Oncological features of sporadic vs. hereditary pediatric medullary thyroid cancer.
Machens A; Lorenz K; Weber F; Dralle H
Endocrine; 2024 Sep; 85(3):1091-1095. PubMed ID: 39003661
[TBL] [Abstract] [Full Text] [Related]
15. Ganglioneuromatous polyposis associated with type 2 B multiple endocrine neoplasia (MEN 2B) - case report.
Rycyk-Bojarzyńska A; Kasztelan-Szczerbińska B; Cichoż-Lach H; Jargieło A
Ann Agric Environ Med; 2024 Jun; 31(2):302-305. PubMed ID: 38940117
[TBL] [Abstract] [Full Text] [Related]
16. Generation of Myeloid-Derived Suppressor cells Mediated by MicroRNA-125a-5p in Melanoma.
Lasser S; Ozbay Kurt FG; Fritz L; Gutzeit N; De La Torre C; Altevogt P; Utikal J; Umansky V
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928399
[TBL] [Abstract] [Full Text] [Related]
17. Critically evaluated key points on hereditary medullary thyroid carcinoma.
Zhang D; Liang N; Sun H; Frattini F; Sui C; Yang M; Wang H; Dionigi G
Front Endocrinol (Lausanne); 2024; 15():1412942. PubMed ID: 38919477
[TBL] [Abstract] [Full Text] [Related]
18. Comparative Performance Analysis of Idylla and Archer in the Detection of Gene Fusions in Spitzoid Melanocytic tumors.
Ebbelaar CF; van Dijk M; Breimer GE; Meijers RWJ; Klein LBC; Petronilia MM; de Leng WWJ; Blokx WAM; Jansen AML;
Mod Pathol; 2024 Aug; 37(8):100538. PubMed ID: 38880351
[TBL] [Abstract] [Full Text] [Related]
19. Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma.
Gigliotti BJ; Brooks JA; Wirth LJ
Mol Cell Endocrinol; 2024 Oct; 592():112295. PubMed ID: 38871174
[TBL] [Abstract] [Full Text] [Related]
20. The role of the adrenalectomy in the management of pheochromocytoma: the experience of a Portuguese referral center.
Carvalho IC; Machado MVB; Morais JP; Carvalho F; Barbosa E; Barbosa J
Endocrine; 2024 Oct; 86(1):409-416. PubMed ID: 38849646
[TBL] [Abstract] [Full Text] [Related]
[Next]